1	The	The	B-NP	DT	O	3	NMOD
2	differential	differential	I-NP	JJ	O	3	NMOD
3	diagnosis	diagnosis	I-NP	NN	O	12	NMOD
4	of	of	B-PP	IN	O	3	NMOD
5	early	early	B-NP	JJ	O	8	NMOD
6	gastric	gastric	I-NP	JJ	O	8	NMOD
7	mucosa-associated	mucosa-associated	I-NP	JJ	O	8	NMOD
8	lymphoma	lymphoma	I-NP	NN	O	4	PMOD
9	:	:	O	:	O	3	P
10	polymerase	polymerase	B-NP	NN	O	12	NMOD
11	chain	chain	I-NP	NN	O	12	NMOD
12	reaction	reaction	I-NP	NN	O	16	NMOD
13	and	and	O	CC	O	16	NMOD
14	paraffin	paraffin	B-NP	NN	O	16	NMOD
15	section	section	I-NP	NN	O	16	NMOD
16	immunophenotyping	immunophenotyping	I-NP	NN	O	0	ROOT
17	.	.	O	.	O	16	P

1	The	The	B-NP	DT	O	2	NMOD
2	distinction	distinction	I-NP	NN	O	18	SUB
3	between	between	B-PP	IN	O	2	NMOD
4	benign	benign	B-NP	JJ	O	7	NMOD
5	florid	florid	I-NP	NN	O	7	NMOD
6	lymphoid	lymphoid	I-NP	JJ	O	7	NMOD
7	hyperplasia	hyperplasia	I-NP	NN	O	13	NMOD
8	and	and	O	CC	O	13	NMOD
9	low-grade	low-grade	B-NP	JJ	O	13	NMOD
10	gastric	gastric	I-NP	JJ	O	13	NMOD
11	mucosal-associated	mucosal-associated	I-NP	JJ	O	13	NMOD
12	lymphoid	lymphoid	I-NP	JJ	O	13	NMOD
13	tissue	tissue	I-NP	NN	O	17	NMOD
14	(	(	O	(	O	16	DEP
15	MALT	MALT	B-NP	NN	O	16	DEP
16	)	)	O	)	O	13	NMOD
17	lymphoma	lymphoma	B-NP	NN	O	3	PMOD
18	may	may	B-VP	MD	O	0	ROOT
19	be	be	I-VP	VB	O	18	VC
20	a	a	B-NP	DT	O	21	NMOD
21	challenge	challenge	I-NP	NN	O	19	PRD
22	.	.	O	.	O	18	P

1	The	The	B-NP	DT	O	2	NMOD
2	presence	presence	I-NP	NN	O	12	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	monoclonal	monoclonal	B-NP	JJ	B-cell_type	6	NMOD
5	B	B	I-NP	NN	I-cell_type	6	NMOD
6	cells	cell	I-NP	NNS	I-cell_type	3	PMOD
7	in	in	B-PP	IN	O	2	NMOD
8	Helicobacter	Helicobacter	B-NP	NNP	O	11	NMOD
9	pylori-chronic	pylori-chronic	I-NP	JJ	O	11	NMOD
10	active	active	I-NP	JJ	O	11	NMOD
11	gastritis	gastritis	I-NP	NN	O	7	PMOD
12	has	have	B-VP	VBZ	O	0	ROOT
13	suggested	suggest	I-VP	VBN	O	12	VC
14	that	that	B-SBAR	IN	O	13	VMOD
15	polymerase	polymerase	B-NP	NN	O	17	NMOD
16	chain	chain	I-NP	NN	O	17	NMOD
17	reaction	reaction	I-NP	NN	O	21	NMOD
18	(	(	O	(	O	20	DEP
19	PCR	PCR	B-NP	NN	O	20	DEP
20	)	)	O	)	O	17	NMOD
21	data	datum	B-NP	NNS	O	22	SUB
22	should	should	B-VP	MD	O	14	SBAR
23	be	be	I-VP	VB	O	22	VC
24	viewed	view	I-VP	VBN	O	23	VC
25	with	with	B-PP	IN	O	24	VMOD
26	caution	caution	B-NP	NN	O	25	PMOD
27	.	.	O	.	O	12	P

1	We	We	B-NP	PRP	O	2	SUB
2	investigated	investigate	B-VP	VBD	O	0	ROOT
3	the	the	B-NP	DT	O	4	NMOD
4	reliability	reliability	I-NP	NN	O	2	OBJ
5	of	of	B-PP	IN	O	4	NMOD
6	PCR	PCR	B-NP	NN	O	8	NMOD
7	versus	versus	I-NP	CC	O	8	NMOD
8	immunophenotyping	immunophenotyping	I-NP	NN	O	5	PMOD
9	in	in	B-PP	IN	O	4	NMOD
10	diagnosing	diagnose	B-VP	VBG	O	9	PMOD
11	early	early	B-NP	JJ	O	14	NMOD
12	gastric	gastric	I-NP	JJ	O	14	NMOD
13	MALT	MALT	I-NP	NN	O	14	NMOD
14	lymphoma	lymphoma	I-NP	NN	O	10	OBJ
15	.	.	O	.	O	2	P

1	We	We	B-NP	PRP	O	2	SUB
2	studied	study	B-VP	VBD	O	0	ROOT
3	1511	1511	B-NP	CD	O	4	NMOD
4	biopsies	biopsy	I-NP	NNS	O	20	NMOD
5	from	from	B-PP	IN	O	4	NMOD
6	eight	eight	B-NP	CD	O	7	NMOD
7	patients	patient	I-NP	NNS	O	5	PMOD
8	with	with	B-PP	IN	O	7	NMOD
9	high-grade	high-grade	B-NP	JJ	O	12	NMOD
10	primary	primary	I-NP	JJ	O	12	NMOD
11	gastric	gastric	I-NP	JJ	O	12	NMOD
12	lymphoma	lymphoma	I-NP	NN	O	8	PMOD
13	,	,	O	,	O	20	P
14	25	25	B-NP	CD	O	20	NMOD
15	with	with	B-PP	IN	O	14	NMOD
16	low-grade	low-grade	B-NP	JJ	O	18	NMOD
17	MALT	MALT	I-NP	NN	O	18	NMOD
18	lymphoma	lymphoma	I-NP	NN	O	15	PMOD
19	,	,	O	,	O	20	P
20	32	32	B-NP	CD	O	27	NMOD
21	with	with	B-PP	IN	O	20	NMOD
22	atypical	atypical	B-NP	JJ	B-cell_type	24	NMOD
23	lymphoid	lymphoid	I-NP	JJ	I-cell_type	24	NMOD
24	infiltrates	infiltrate	I-NP	NNS	I-cell_type	21	PMOD
25	,	,	O	,	O	20	P
26	and	and	O	CC	O	27	NMOD
27	39	39	B-NP	CD	O	2	OBJ
28	with	with	B-PP	IN	O	27	NMOD
29	Helicobacter	Helicobacter	B-NP	NN	O	32	NMOD
30	pylori-chronic	pylori-chronic	I-NP	JJ	O	32	NMOD
31	active	active	I-NP	JJ	O	32	NMOD
32	gastritis	gastritis	I-NP	NN	O	28	PMOD
33	.	.	O	.	O	2	P

1	Paraffin	Paraffin	B-NP	NN	O	2	NMOD
2	sections	section	I-NP	NNS	O	6	SUB
3	from	from	B-PP	IN	O	2	NMOD
4	all	all	B-NP	DT	O	5	NMOD
5	cases	case	I-NP	NNS	O	3	PMOD
6	were	be	B-VP	VBD	O	0	ROOT
7	stained	stain	I-VP	VBN	O	6	VC
8	with	with	B-PP	IN	O	7	VMOD
9	antibodies	antibody	B-NP	NNS	B-protein	8	PMOD
10	to	to	B-PP	TO	O	9	NMOD
11	CD20	CD20	B-NP	NN	B-protein	19	NMOD
12	,	,	I-NP	,	O	19	P
13	CD3	CD3	I-NP	NN	B-protein	19	NMOD
14	,	,	I-NP	,	O	19	P
15	AE1/AE3	AE1/AE3	I-NP	NN	O	19	NMOD
16	,	,	I-NP	,	O	19	P
17	kappa	kappa	I-NP	NN	O	19	NMOD
18	and	and	I-NP	CC	O	19	NMOD
19	lambda	lambda	I-NP	NN	O	10	PMOD
20	.	.	O	.	O	6	P

1	PCR	PCR	B-NP	NN	O	2	SUB
2	was	be	B-VP	VBD	O	0	ROOT
3	performed	perform	I-VP	VBN	O	2	VC
4	on	on	B-PP	IN	O	3	VMOD
5	paraffin	paraffin	B-NP	NN	O	6	NMOD
6	sections	section	I-NP	NNS	O	4	PMOD
7	using	use	B-VP	VBG	O	2	VMOD
8	the	the	B-NP	DT	O	11	NMOD
9	primer	primer	I-NP	NN	O	11	NMOD
10	set	set	I-NP	NN	O	11	NMOD
11	VH-FR3/J	VH-FR3/J	I-NP	NN	O	7	OBJ
12	(	(	O	(	O	14	DEP
13	H	H	B-NP	NN	O	14	DEP
14	)	)	O	)	O	11	NMOD
15	.	.	O	.	O	2	P

1	Using	Use	B-VP	VBG	O	11	VMOD
2	histopathology	histopathology	B-NP	NN	O	1	OBJ
3	as	as	B-PP	IN	O	1	VMOD
4	the	the	B-NP	DT	O	6	NMOD
5	gold	gold	I-NP	JJ	O	6	NMOD
6	standard	standard	I-NP	NN	O	3	PMOD
7	in	in	B-PP	IN	O	6	NMOD
8	diagnosis	diagnosis	B-NP	NN	O	7	PMOD
9	,	,	O	,	O	11	P
10	we	we	B-NP	PRP	O	11	SUB
11	confirmed	confirm	B-VP	VBD	O	27	VMOD
12	monoclonality	monoclonality	B-NP	NN	O	11	OBJ
13	in	in	B-PP	IN	O	11	VMOD
14	22	22	B-NP	CD	O	15	AMOD
15	of	of	B-PP	IN	O	13	PMOD
16	25	25	B-NP	CD	O	18	NMOD
17	MALT	MALT	I-NP	NN	O	18	NMOD
18	lymphomas	lymphoma	I-NP	NNS	O	15	PMOD
19	(	(	O	(	O	22	DEP
20	88	88	B-NP	CD	O	21	NMOD
21	%	%	I-NP	NN	O	22	DEP
22	)	)	O	)	O	18	NMOD
23	;	;	O	:	O	11	P
24	a	a	B-NP	DT	O	26	NMOD
25	clonal	clonal	I-NP	JJ	O	26	NMOD
26	band	band	I-NP	NN	O	27	SUB
27	was	be	B-VP	VBD	O	0	ROOT
28	found	find	I-VP	VBN	O	27	VC
29	in	in	B-PP	IN	O	28	VMOD
30	38	38	B-NP	CD	O	31	NMOD
31	%	%	I-NP	NN	O	29	PMOD
32	(	(	O	(	O	36	DEP
33	15	15	B-NP	CD	O	34	AMOD
34	of	of	B-PP	IN	O	36	DEP
35	39	39	B-NP	CD	O	34	AMOD
36	)	)	O	)	O	31	NMOD
37	of	of	B-PP	IN	O	31	NMOD
38	patients	patient	B-NP	NNS	O	37	PMOD
39	with	with	B-PP	IN	O	38	NMOD
40	chronic	chronic	B-NP	JJ	O	42	NMOD
41	active	active	I-NP	JJ	O	42	NMOD
42	gastritis	gastritis	I-NP	NN	O	39	PMOD
43	.	.	O	.	O	27	P

1	An	An	B-NP	DT	O	3	NMOD
2	immunophenotype	immunophenotype	I-NP	NN	O	3	NMOD
3	pattern	pattern	I-NP	NN	O	12	SUB
4	with	with	B-PP	IN	O	3	NMOD
5	predominance	predominance	B-NP	NN	O	4	PMOD
6	of	of	B-PP	IN	O	5	NMOD
7	CD20-positive	CD20-positive	B-NP	JJ	B-cell_type	8	NMOD
8	cells	cell	I-NP	NNS	I-cell_type	6	PMOD
9	in	in	B-PP	IN	O	8	NMOD
10	lymphocytic	lymphocytic	B-NP	JJ	B-cell_type	11	NMOD
11	infiltrates	infiltrate	I-NP	NNS	I-cell_type	9	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	associated	associate	I-VP	VBN	O	12	VC
14	with	with	B-PP	IN	O	13	VMOD
15	monoclonality	monoclonality	B-NP	NN	O	14	PMOD
16	in	in	B-PP	IN	O	15	NMOD
17	92	92	B-NP	CD	O	18	NMOD
18	%	%	I-NP	NN	O	16	PMOD
19	of	of	B-PP	IN	O	18	NMOD
20	cases	case	B-NP	NNS	O	19	PMOD
21	.	.	O	.	O	12	P

1	The	The	B-NP	DT	O	2	NMOD
2	presence	presence	I-NP	NN	O	9	SUB
3	of	of	B-PP	IN	O	2	NMOD
4	an	an	B-NP	DT	O	8	NMOD
5	enlarged	enlarged	I-NP	JJ	O	8	NMOD
6	irregular	irregular	I-NP	JJ	O	8	NMOD
7	mantle	mantle	I-NP	NN	O	8	NMOD
8	zone	zone	I-NP	NN	O	3	PMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	found	find	I-VP	VBN	O	9	VC
11	in	in	B-PP	IN	O	10	VMOD
12	both	both	B-NP	CC	O	15	AMOD
13	monoclonal	monoclonal	I-NP	JJ	O	15	AMOD
14	and	and	I-NP	CC	O	15	AMOD
15	polyclonal	polyclonal	I-NP	JJ	O	16	NMOD
16	areas	area	I-NP	NNS	O	11	PMOD
17	.	.	O	.	O	9	P

1	An	An	B-NP	DT	O	3	NMOD
2	equal	equal	I-NP	JJ	O	3	NMOD
3	prevalence	prevalence	I-NP	NN	O	12	SUB
4	of	of	B-PP	IN	O	3	NMOD
5	B	B	B-NP	NN	B-cell_type	8	NMOD
6	and	and	O	CC	I-cell_type	8	NMOD
7	T	T	B-NP	NN	I-cell_type	8	NMOD
8	cells	cell	B-NP	NNS	I-cell_type	4	PMOD
9	in	in	B-PP	IN	O	3	NMOD
10	lymphocytic	lymphocytic	B-NP	JJ	B-cell_type	11	NMOD
11	infiltrates	infiltrate	I-NP	NNS	I-cell_type	9	PMOD
12	was	be	B-VP	VBD	O	0	ROOT
13	associated	associate	I-VP	VBN	O	12	VC
14	with	with	B-PP	IN	O	13	VMOD
15	a	a	B-NP	DT	O	17	NMOD
16	polyclonal	polyclonal	I-NP	JJ	O	17	NMOD
17	pattern	pattern	I-NP	NN	O	14	PMOD
18	in	in	B-PP	IN	O	17	NMOD
19	24	24	B-NP	CD	O	18	PMOD
20	of	of	B-PP	IN	O	19	NMOD
21	31	31	B-NP	CD	O	22	NMOD
22	cases	case	I-NP	NNS	O	20	PMOD
23	(	(	O	(	O	26	DEP
24	77	77	B-NP	CD	O	25	NMOD
25	%	%	I-NP	NN	O	26	DEP
26	)	)	O	)	O	19	NMOD
27	.	.	O	.	O	12	P

1	Immunostaining	Immunostaining	B-NP	NN	O	9	SUB
2	of	of	B-PP	IN	O	1	NMOD
3	sIg	sIg	B-NP	NN	B-protein	2	PMOD
4	(	(	O	(	O	8	DEP
5	kappa	kappa	B-NP	NN	O	7	NMOD
6	and	and	O	CC	O	7	NMOD
7	lambda	lambda	B-NP	NN	O	8	DEP
8	)	)	O	)	O	1	NMOD
9	was	be	B-VP	VBD	O	0	ROOT
10	difficult	difficult	B-ADJP	JJ	O	9	PRD
11	in	in	B-PP	IN	O	9	VMOD
12	paraffin	paraffin	B-NP	NN	O	13	NMOD
13	sections	section	I-NP	NNS	O	19	SUB
14	and	and	O	CC	O	19	VMOD
15	convincing	convince	B-VP	VBG	O	19	SUB
16	proof	proof	B-NP	NN	O	15	OBJ
17	of	of	B-PP	IN	O	16	NMOD
18	monoclonality	monoclonality	B-NP	NN	O	17	PMOD
19	was	be	B-VP	VBD	O	11	SBAR
20	not	not	I-VP	RB	O	19	VMOD
21	obtained	obtain	I-VP	VBN	O	19	VC
22	.	.	O	.	O	9	P

1	Lymphoepithelial	Lymphoepithelial	B-NP	JJ	O	2	NMOD
2	lesions	lesion	I-NP	NNS	O	3	SUB
3	were	be	B-VP	VBD	O	11	VMOD
4	infrequent	infrequent	B-ADJP	JJ	O	3	PRD
5	in	in	B-PP	IN	O	4	AMOD
6	gastric	gastric	B-NP	JJ	O	7	NMOD
7	biopsies	biopsy	I-NP	NNS	O	5	PMOD
8	and	and	O	CC	O	11	VMOD
9	their	their	B-NP	PRP$	O	10	NMOD
10	presence	presence	I-NP	NN	O	11	SUB
11	was	be	B-VP	VBD	O	0	ROOT
12	highlighted	highlight	I-VP	VBN	O	11	VC
13	with	with	B-PP	IN	O	12	VMOD
14	keratin	keratin	B-NP	NN	O	15	NMOD
15	stains	stain	I-NP	NNS	O	13	PMOD
16	.	.	O	.	O	11	P

1	Because	Because	B-SBAR	IN	O	19	VMOD
2	monoclonal	monoclonal	B-NP	JJ	B-cell_type	4	NMOD
3	B	B	I-NP	NN	I-cell_type	4	NMOD
4	cells	cell	I-NP	NNS	I-cell_type	5	SUB
5	are	be	B-VP	VBP	O	1	SBAR
6	observed	observe	I-VP	VBN	O	5	VC
7	in	in	B-PP	IN	O	6	VMOD
8	Helicobacter	Helicobacter	B-NP	NNP	O	10	NMOD
9	pylori-associated	pylori-associated	I-NP	JJ	O	10	NMOD
10	gastritis	gastritis	I-NP	NN	O	7	PMOD
11	,	,	O	,	O	19	P
12	the	the	B-NP	DT	O	14	NMOD
13	correct	correct	I-NP	JJ	O	14	NMOD
14	interpretation	interpretation	I-NP	NN	O	19	SUB
15	of	of	B-PP	IN	O	14	NMOD
16	clonality	clonality	B-NP	NN	O	15	PMOD
17	by	by	B-PP	IN	O	14	NMOD
18	PCR	PCR	B-NP	NN	O	17	PMOD
19	remains	remain	B-VP	VBZ	O	0	ROOT
20	unclear	unclear	B-ADJP	JJ	O	19	PRD
21	.	.	O	.	O	19	P

1	Paraffin	Paraffin	B-NP	NN	O	3	NMOD
2	section	section	I-NP	NN	O	3	NMOD
3	IHC	IHC	I-NP	NN	O	8	SUB
4	using	use	B-VP	VBG	O	3	NMOD
5	CD20	CD20	B-NP	NN	B-protein	7	NMOD
6	and	and	I-NP	CC	O	7	NMOD
7	CD3	CD3	I-NP	NN	B-protein	4	OBJ
8	is	be	B-VP	VBZ	O	0	ROOT
9	especially	especially	B-ADJP	RB	O	10	AMOD
10	useful	useful	I-ADJP	JJ	O	8	PRD
11	to	to	B-VP	TO	O	12	VMOD
12	confirm	confirm	I-VP	VB	O	10	AMOD
13	the	the	B-NP	DT	O	14	NMOD
14	diagnosis	diagnosis	I-NP	NN	O	12	OBJ
15	of	of	B-PP	IN	O	14	NMOD
16	gastric	gastric	B-NP	JJ	O	18	NMOD
17	MALT	MALT	I-NP	NN	O	18	NMOD
18	lymphoma	lymphoma	I-NP	NN	O	15	PMOD
19	.	.	O	.	O	8	P

